Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group Limited announced that its SYH2059 Tablets have received clinical trial approval in China. This product, a PDE4B inhibitor, has shown superior efficacy and safety in preclinical studies for treating interstitial lung disease, a condition with limited current treatment options, marking a promising advancement in medical therapeutics.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company based in Hong Kong, focusing on the pharmaceutical industry. It specializes in innovative drug development, with a market focus that includes treatments for various diseases. The company is known for its development of novel small molecule drugs, possessing independent intellectual property rights.
YTD Price Performance: -0.34%
Average Trading Volume: 8,827
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.86B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.
